Sign Up to like & get
recommendations!
1
Published in 2022 at "Hepatology"
DOI: 10.1002/hep.32393
Abstract: BACKGROUND & AIMS Sofosbuvir-velpatasvir-voxilaprevir is a pangenotypic regimen for chronic hepatitis C virus (HCV) infection. In the United States and Europe, sofosbuvir-velpatasvir-voxilaprevir once daily for 12 weeks is indicated for adults previously receiving an HCV…
read more here.
Keywords:
infection;
velpatasvir voxilaprevir;
sofosbuvir velpatasvir;
hepatitis virus ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Digestive and Liver Disease"
DOI: 10.1016/j.dld.2018.11.063
Abstract: Division of Gastroenterology and Hepatology, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
[email protected] E. Degasperi1, A. Spinetti2, A. Lombardi3, S. Landonio4, P. G. Scotton5, L. Pasulo6, P. Pozzoni7, A. Giorgini8, P. Fabris9, A. Romano10, L. Lomonaco11,…
read more here.
Keywords:
effectiveness safety;
sofosbuvir velpatasvir;
retreatment chronic;
voxilaprevir retreatment ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2018.1459567
Abstract: ABSTRACT Introduction: Hepatitis C is a disease with a significant global impact. Over the last several years, the treatment of the disease has been revolutionized. Therapy has transformed over the last several years with the…
read more here.
Keywords:
sofosbuvir velpatasvir;
hepatitis;
treatment;
treatment hepatitis ... See more keywords